临床药物手册( 英文原版)7.pdfVIP

  1. 1、本文档共36页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  5. 5、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  6. 6、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  7. 7、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  8. 8、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
临床药物手册( 英文原版)7

Hematologic Drugs Coagulants and Anticoagulants ABCIXIMAB ReoPro Pharmacology. Abciximab is a chimeric human-murine monoclonal antibody Fab fragment that binds to and irreversibly inhibits the platelet glycoprotein IIb/IIIa receptor. Blockade of the glycoprotein IIb/IIIa receptor prevents fibrino- gen from binding, thereby inhibiting platelet aggregation. Abciximab also binds to the vitronectin receptor found on platelets, endothelial cells, monocytes, and smooth muscle cells; the clinical relevance of this is unknown. Abciximab inhibits platelet aggregation and prolongs bleeding time in a dose-dependent manner.1,2 Administration and Adult Dosage. IV for percutaneous coronary intervention 0.25 mg/kg as a bolus 10–60 min before starting percutaneous coronary interven- tion and then 0.125 µg/kg/min (up to 10 µg/min) by continuous infusion for 12 hr. IV for unstable angina and planned percutaneous intervention within 24 hr 0.25 mg/kg as a bolus and then 0.125 µg/kg/min (up to 10 µg/min) by continuous infusion for 18–24 hr, concluding 1 hr after the percutaneous coronary interven- tion. (See Parameters to Monitor and Notes.) Special Populations. Geriatric Dosage. Same as adult dosage. Dosage Forms. Inj 2 mg/mL. Pharmacokinetics. Onset and Duration. Rapid inhibition of platelet function after IV administration. Platelet function gradually recovers after discontinuation of the IV infusion; bleeding time approaches baseline values within 24 hr and ex vivo platelet aggregation approaches baseline levels within 48 hr. Low levels of glyco- protein IIb/IIIa inhibition are detectable for up to 14 days after administration.1 Fate. Abciximab is rapidly cleared from the plasma after administration by rapid binding to the glycoprotein IIb/IIIa recept

文档评论(0)

jiupshaieuk12 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

版权声明书
用户编号:6212135231000003

1亿VIP精品文档

相关文档